Research Site

Solvang, California 93463

1 studies enrolling now · 2 studies all time

What they study most

ER-Positive HER2-Negative Breast Cancer, Gastroesophageal Junction Adenocarcinoma, HER2-positive Gastric Cancer

Studies at this site

• A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer — Recruiting now
• A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease — Running, not enrolling